Jun 2026 (Q2 FY26) — Aug 5, 2026
ADMA Biologics Q2 FY26 — Strong ASCENIV Growth and Pipeline Advancement
Read the full callADMA Biologics (ADMA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
ADMA Biologics earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 124 | +2.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 42.2 | +7.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 37.8 | +10.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$11.07 +3.65% · +$0.39
Performance −22.9% 1Y
1Y: $14.36 on 17 Oct 2025 → $11.07. High $20.38 (11 Dec 2025), low $7.6 (2 Jun 2026).
- Previous close
- $10.68
- 52-week range
- $7.6 – $20.38
- One year
- −24.64%
Overview
- Symbol
- ADMA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
ADMA Biologics earnings calls (ADMA)
Financials
What the filings say
Net profit, year on year: +11% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 120 | 118 | 115 | 122 | 134 | 139 | 114 | 124 |
| Operating profit | 40 | 38 | 35 | 43 | 51 | 63 | 58 | 52 |
| Operating margin | 33.1% | 32.6% | 30.4% | 35.1% | 38.0% | 45.1% | 50.9% | 42.2% |
| Other income | -3 | -4 | -1 | -3 | -3 | -1 | -1 | -2 |
| Interest | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 37 | 35 | 33 | 40 | 48 | 62 | 57 | 50 |
| Tax rate | 2.3% | −222.3% | 19.6% | 14.7% | 23.3% | 19.8% | 20.6% | 24.7% |
| Net profit | 36 | 112 | 27 | 34 | 36 | 49 | 45 | 38 |
| EPS ($ per share) | 0.15 | — | 0.11 | 0.14 | 0.15 | — | 0.19 | 0.17 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -216 | -265 | -340 | -412 | -478 | -506 | -309 | -162 |
| Total liabilities | 69 | 101 | 119 | 135 | 196 | 194 | 140 | 147 |
| Fixed assets | 30 | 32 | 42 | 51 | 58 | 54 | 55 | 65 |
| Total assets | 89 | 127 | 208 | 276 | 348 | 329 | 489 | 624 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -63 | -76 | -102 | -112 | -60 | 9 | 119 | 50 |
| Cash from investing | -2 | -4 | -13 | -14 | -14 | -5 | -9 | -22 |
| Cash from financing | 43 | 80 | 144 | 121 | 109 | -39 | -58 | -44 |
| Net cash flow | — | — | 29 | -5 | 35 | -35 | 52 | -16 |
| Capital expenditure | -2 | -4 | -13 | -14 | -14 | -5 | -8 | -23 |
| Free cash flow | -65 | -80 | -115 | -126 | -73 | 4 | 110 | 28 |
Insider filings
49 filings between Oct 24, 2025 and Jul 24, 2026.
Open market
decisions to buy or sellPurchases
$468.3K
5 purchases by 2 insiders
Sales
$1.90M
11 sales by 2 insiders
91% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 9
- Award — granted as compensation
- 11
- Option exercise — converted options into shares
- 10
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts, 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Grossman Adam S | — | $1.74M | Mar 16, 2026 |
| Grossman Jerrold B | $250.9K | — | May 27, 2026 |
| ELMS STEVE | $217.4K | — | Mar 6, 2026 |
| Kestenberg-Messina Kaitlin M. | — | $157.8K | Mar 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 24, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Tax withheld | 3,177 | $26.6K |
| Jul 16, 2026 | Kohler Terry CFO and Treasurer | Award | 85,130 | $0 |
| May 27, 2026 | Grossman Jerrold B Director | Purchase | 6,400 | $50.6K |
| May 12, 2026 | Grossman Jerrold B Director | Purchase | 12,500 | $100.1K |
| May 11, 2026 | Grossman Jerrold B Director | Purchase | 12,500 | $100.1K |
| Apr 1, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Tax withheld | 20,362 | $185.5K |
| Mar 17, 2026 | Guiheen Lawrence P. Director | Gift | 30,000 | $0 |
| Mar 17, 2026 | Guiheen Lawrence P. Director | Gift | 30,000 | $0 |
| Mar 16, 2026 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 15,000 | $227.4K |
| Mar 16, 2026 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 6,000 | $91.0K |
| Mar 16, 2026 | Grossman Adam S President and CEO | Option exercise 10b5-1 plan | 15,000 | $81.0K |
| Mar 13, 2026 | Guiheen Lawrence P. Director | Option exercise | 30,000 | $109.8K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Option exercise | 2,175 | $3.4K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Sale | 10,096 | $157.8K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Option exercise | 2,646 | $7.5K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Option exercise | 1,250 | $5.4K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Option exercise | 2,500 | $12.5K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Option exercise | 1,525 | $3.6K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Other | 91,266 | $0 |
| Mar 7, 2026 | Grossman Adam S President and CEO | Tax withheld | 29,513 | $454.2K |
| Mar 7, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Tax withheld | 4,235 | $65.2K |
| Mar 6, 2026 | Grossman Adam S President and CEO | Tax withheld | 56,438 | $868.6K |
| Mar 6, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Tax withheld | 10,059 | $154.8K |
| Mar 6, 2026 | ELMS STEVE Director | Purchase | 7,000 | $107.7K |
| Mar 5, 2026 | ELMS STEVE Director | Purchase | 7,000 | $109.7K |
| Feb 26, 2026 | Grossman Adam S President and CEO | Tax withheld | 54,858 | $832.7K |
| Feb 19, 2026 | Grossman Adam S President and CEO | Tax withheld | 24,793 | $404.6K |
| Feb 19, 2026 | Tade Brad L. CFO and Treasurer | Tax withheld | 6,479 | $105.7K |
| Feb 19, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Tax withheld | 8,161 | $133.2K |
| Feb 17, 2026 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 15,000 | $241.2K |
| Feb 17, 2026 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 6,000 | $96.5K |
| Feb 17, 2026 | Grossman Adam S President and CEO | Option exercise 10b5-1 plan | 15,000 | $81.0K |
| Feb 9, 2026 | Guiheen Lawrence P. Director | Award | 10,690 | $0 |
| Feb 9, 2026 | ELMS STEVE Director | Award | 10,690 | $0 |
| Feb 9, 2026 | Grossman Jerrold B Director | Award | 10,690 | $0 |
| Feb 9, 2026 | Kestenberg-Messina Kaitlin M. COO and SVP, Compliance | Award | 91,631 | $0 |
| Feb 9, 2026 | Grossman Adam S President and CEO | Award | 282,529 | $0 |
| Feb 9, 2026 | KWON YOUNG Director | Award | 10,690 | $0 |
| Feb 9, 2026 | FINGER ALISON CECILY Director | Award | 10,690 | $0 |
| Feb 9, 2026 | Salas Eduardo Rene Director | Award | 10,690 | $0 |
| Dec 15, 2025 | Grossman Adam S President and CEO | Option exercise 10b5-1 plan | 15,000 | $81.0K |
| Dec 15, 2025 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 6,000 | $118.7K |
| Dec 15, 2025 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 15,000 | $296.9K |
| Nov 19, 2025 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 6,000 | $96.0K |
| Nov 19, 2025 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 15,000 | $240.0K |
| Nov 19, 2025 | Grossman Adam S President and CEO | Option exercise 10b5-1 plan | 15,000 | $81.0K |
| Oct 24, 2025 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 6,000 | $96.0K |
| Oct 24, 2025 | Grossman Adam S President and CEO | Sale 10b5-1 plan | 15,000 | $240.0K |
| Oct 24, 2025 | Grossman Adam S President and CEO | Option exercise 10b5-1 plan | 15,000 | $81.0K |
| Sep 15, 2025 | Grossman Adam S President and CEO | Option exercise 10b5-1 plan | 15,000 | $81.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ADMA BIOLOGICS, INC.
Free account. Everything above stays public.
Write why you follow ADMA BIOLOGICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading